You just read:

Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival

News provided by

Amgen

Sep 13, 2019, 09:00 ET